James Alexander, UEG Week 2022: Antibody and T-cell Response to the Third COVID-19 Vaccine Dose in Immunosuppressed Patients with Inflammatory Bowel Disease
The VIP study was a multicentre, prospective, case-control study, investigating whether immunosuppressive treatments reduced antibody and T-cell responses in patients with inflammatory bowel disease (IBD) after a third COVID-19 vaccine dose. In this touchIMMUNOLOGY interview, we speak with Dr. James Alexander (Imperial College London, London, UK) to discuss the aims, methodology and findings from the VIP study.
The abstract entitled ‘COVID-19 VACCINE-INDUCED ANTIBODY AND T CELL RESPONSES IN IMMUNOSUPPRESSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE AFTER THE THIRD VACCINE DOSE’ (Abstract no: LB15) was presented at UEG Week, October 8 – 11, 2022.
Questions
- Why is it important for immunosuppressed patients to be prioritised for booster doses of the COVID vaccine? (0:16)
- What was previously known about the effect of immunosuppressive treatments on antibody and T-cell responses in patients with inflammatory bowel disease (IBD)? (0:58)
- What were the aims and methodology of the VIP study? (1:59)
- What immunosuppressive treatments had an impact on antibody and T-cell responses after a third vaccine dose? (3:26)
- What impact will these findings have on vaccine booster dosing? (4:49)
Disclosures: James Alexander has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed as a highlight of UEG Week 2022.
